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Daytime Variation in serum 
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Fertilization Treatment
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and Peter Humaidan1,2
1 The Fertility Clinic, Skive Regional Hospital, Skive, Denmark, 2 Department of Clinical Medicine, Aarhus University, Aarhus, 
Denmark, 3 The Fertility Clinic, Herlev Hospital, Herlev, Denmark, 4 Department of Clinical Medicine, University of 
Copenhagen, Copenhagen, Denmark, 5 Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children 
and Reproduction, University Hospital of Copenhagen, University of Copenhagen, Copenhagen, Denmark
Objective: To investigate whether mid-luteal serum progesterone (P4) exhibits significant 
fluctuations during a 12-h daytime period in women undergoing in vitro fertilization (IVF) 
and to explore whether the extent of these fluctuations could impact the interpretation of 
luteal progesterone levels in a clinical setting.
Design: Explorative pilot study.
setting: Public hospital-based fertility unit.
Patients: Ten women undergoing IVF treatment.
intervention: Seven days after oocyte pick-up, patients underwent frequent repeated 
blood sampling (every 60 min for 12 h and during two of these hours, every 15 min). 
Serum samples were analyzed for progesterone, estradiol, and luteinizing hormone (LH).
Main outcome measures: Daytime fluctuations in s-progesterone and s-estradiol.
results: There was a significant positive correlation between median P4 levels and the 
magnitude of P4 variations—women with median P4 < 60 nmol/l had clinically stable P4 
levels throughout the day, while patients with median P4 > 250 nmol/l exhibited periodic 
P4 peaks of several hundred nanomoles per liter. These endogenous P4 fluctuations were 
observed irrespective of the type of stimulation protocol or mode of triggering of final 
oocyte maturation and despite the fact that LH was under the detection limit at the time 
of measurement. Simultaneously, large fluctuations were seen in s-estradiol.
conclusion: Monitoring of early to mid-luteal P4 levels in IVF cycles may be valuable in 
the planning of individualized luteal phase support in the attempt to increase reproduc-
tive outcomes. The prerequisite for luteal phase monitoring is, however, that the validity 
of a single measured P4 value is reliable. We show for the first time, that a single P4 
measurement in the low progesterone patient quite accurately reflects the corpus luteum 
function and that the measurement can be used to detect IVF patients with a need of 
additional exogenous luteal P4 administration.
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inTrODUcTiOn
The human corpus luteum (CL) is a transient ovarian endocrine 
gland, which is active during the luteal phase of the menstrual 
cycle and in early pregnancy until gestational week 8. The CL pro-
duces significant amounts of progesterone (P4), estradiol (E2), and 
androgens as well as growth factors and nonsteroidal hormones. 
The overall maintenance of CL function is critically depend-
ent upon regular stimulation of pituitary luteinizing hormone 
(LH) or human chorionic gonadotropin (hCG) to sustain the 
steroidogenesis from the luteinized granulosa and theca cells (1). 
A sufficient P4 production from the CL is an absolute necessity for 
the decidualization of the endometrium preceding implantation 
and the establishment of early pregnancy. Progesterone secretion 
from the CL is maximal during the mid-luteal phase inducing 
a serum P4 level of approximately 40–60  nmol/l in the natural 
cycle (2, 3).
During ovarian stimulation for in  vitro fertilization (IVF) 
supra-physiological levels of E2 are obtained during the late fol-
licular phase as a result of the multifollicular growth. This hyper-
estrogenic state must be counterbalanced in the luteal phase by an 
increased P4 load to achieve a receptive endometrium in time for 
embryo transfer. Previously, Humaidan and co-workers showed 
that the use of GnRH agonist trigger in IVF cycles followed by a 
standard vaginal luteal phase support resulted in mid-luteal P4 
levels comparable to levels seen in the natural cycle (39 nmol/l) 
(4). However, in contrast to what was expected, this P4 level was 
too low to secure successful implantation and pregnancy, resulting 
in an ongoing IVF pregnancy rate of only 6%. Thus, emphasizing 
the fact that the P4 requirement during the luteal phase of the 
stimulated cycle is greater than that of the natural cycle. When 
the luteal phase support was modified by adding a bolus of 1,500 
IU hCG on the day of oocyte retrieval, the mid-luteal P4 level 
of the GnRHa triggered cycle increased to 74  nmol/l resulting 
in a delivery rate of 24% per transfer (5). It seems that a mid-
luteal serum P4 threshold of approximately 80–100 nmol/l exists 
after IVF treatment followed by fresh embryo transfer, and that 
this threshold must be surpassed in order to secure a successful 
reproductive outcome (6). The traditional luteal phase support in 
artificial IVF cycles with administration of vaginal micronized P4 
induces a luteal serum P4 level of approximately 40 nmol/l (7–9). 
Thus, a substantial additional endogenous P4 production by the 
CL is mandatory to surpass the P4 threshold to subsequently 
optimize the chance of pregnancy following IVF treatment. 
Traditionally, clinicians do not monitor the luteal phase P4 levels 
in the firm belief that the luteal phase support will cover the P4 
need of the cycle. However, we have previously seen that more 
than 25% of IVF patients in both the hCG and GnRHa triggered 
group have a mid-luteal serum P4 below 60 nmol/l despite luteal 
phase support and the fact that they had more than 14 follicles on 
the day of aspiration (10). Furthermore, data from non-human 
species (11, 12) and data from human frozen/thawed embryo 
cycles (13, 14) have shown that an optimal luteal P4 range exists 
and that pregnancy outcome is reduced not only below but also 
above this optimal P4 level. Whether this is also the case following 
IVF and fresh embryo transfer, is still to be explored. If this is 
the case, monitoring of luteal P4 levels may help to improve the 
reproductive outcome in IVF cycles by allowing an individualiza-
tion of treatment based on the serum P4 measurements.
However, mid-luteal P4 measurements are complicated by the 
pulsatile nature of hormone secretion from the CL. Filicori and 
co-workers (15) showed that plasma P4 concentrations exhibit 
large and rapid fluctuations during the mid-luteal phase of 
naturally cycling women. Thus, P4 levels ranged from values as 
low as 7 nmol/l to peaks of 128 nmol/l within minutes during a 
24-h study period. In the natural cycle, two distinguishable types 
of P4 pulses exist during the mid-luteal phase: those preceded by 
an LH pulse and others emerging at time of LH quiescence; the 
latter being a result of an autonomous steroid secretion by the CL 
independent of LH activity. During the mid-luteal phase of the 
stimulated IVF cycle, the pituitary is suppressed by the negative 
feedback from supra-physiological steroid levels and s-LH is sig-
nificantly reduced to levels much lower (0.5–0.7 IU/l) than seen 
in the mid-luteal phase of the natural cycle (5–7 IU/l) (16–18). 
How this diminished LH pulse activity influences the secretory 
pattern of ovarian steroidogenesis during the mid-luteal phase of 
an IVF cycle is until now unknown.
The present study was performed to explore whether mid-
luteal serum P4 levels in an IVF cycle exhibit a similar high-
pulsatile pattern as seen during the natural cycle, knowing that 
the LH pulse activity is distinctly reduced. From a clinical point 
of view, we wanted to investigate whether a single morning P4 
measurement provided a reliable index of mid-luteal CL function 
following IVF treatment.
MaTerials anD MeThODs
study Population
Ten female patients undergoing IVF/ICSI at the Fertility Clinic in 
Skive, Denmark, from December 2014 to December 2015 volun-
teered to participate in the study. Clinical information regarding 
age, body mass index (BMI), smoking habits, biochemical repro-
ductive profile, cause of infertility, prior IVF attempts, course 
of stimulation, and laboratory results were recorded. Baseline 
characteristics of participants are provided in Table  1. Written 
informed consent was obtained from all patients prior to study 
participation. Participants were chosen so as to represent both 
the long GnRH agonist cycle as well the GnRH antagonist cycle 
and different types of triggering for final oocyte maturation (hCG 
or GnRH agonist).
Protocols for Ovarian stimulation
Six patients were treated in a long GnRH agonist cycle with 
pituitary suppression using SC injection of Buserelin 0.8  mg 
(Suprefact®; Sanofi, Denmark) starting in the mid-luteal phase 
of the preceding cycle. A daily dose of 0.4  mg Buserelin was 
administered until the day before ovulation triggering. On day 2 
of the cycle, a transvaginal ultrasound examination was carried 
out, and in case of an endometrial thickness <  4 mm, ovarian 
stimulation started with corifollitropin-alfa (Elonva®; MSD, 
Denmark) in combination with either r-FSH/rLH (Pergoveris®; 
Merck Biopharma, Denmark) or hMG (Menopur®, Ferring 
Pharmaceuticals, Denmark). The gonadotropin dosage was 
Table 1 | Description of demographic data, ovarian stimulation, luteal phase support, and progesterone levels in study patients.
Patient age (years) body mass 
index (kg/m2)
basal  
Fsh (iU/l)
cause of 
infertility
Protocol Total Fsh 
sum (iU)
Duration of 
Fsh stimulation 
(days)
Ovulation trigger luteal phase  
support
no. of  
follicles >  
14 mm
no. of 
oocytes
no. of 
Mii
Mid-luteal P4 
(nmol/l)
1 38 24.4 6.5 Male factor Long GnRHa 3,225 11 hCG 10,000 IU Lutinus 300 mg daily 5 5 1 89
2 37 22.8 6.6 No male partner/
endometriosis
GnRH 
antagonist
1,725 9 Suprefact 0.5 mg Lutinus 300 mg 
daily + 1,500 hCG 
(OPU) + 1,000 hCG 
(OPU + 5)
10 11 10 283
3 39 30.0 6.4 No male partner Long GnRHa 3,450 12 Ovitrelle 6,500 IU Lutinus 300 mg daily 14 12 12 277
4 34 22.2 14.7 Unexplained Long GnRHa 3,600 12 hCG 10,000 IU Lutinus 300 mg daily 9 8 8 213
5 28 19.9 5.9 Male factor Long GnRHa 2,925 11 hCG 10,000 IU Lutinus 300 mg daily 9 6 3 97
6 37 25.3 8.3 Unexplained Long GnRHa 3,600 12 Ovitrelle 6,500 IU Lutinus 300 mg daily 11 8 8 376
7 28 31.8 3.9 Endometriosis GnRH 
antagonist
2,025 9 Suprefact 0.5 mg Crinone 180 
daily + 1,500 hCG 
(OPU)
17 11 11 36
8 36 25.6 4.9 Tubal factor GnRH 
antagonist
1,913 9 Suprefact 0.5 mg Crinone 180 
daily + 1,500 hCG 
(OPU)
19 13 13 55
9 40 34.5 7.2 Unexplained Long GnRHa 2,250 9 hCG 10,000 IU Lutinus 300 mg daily 7 6 6 54
10 36 29.4 7.2 Male factor GnRH 
antagonist
3,938 15 Suprefact 0.5 mg Lutinus 300 mg 
daily + 1,000 hCG 
(OPU) + 500 (OPU + 5)
20 14 8 161
Mid-luteal P4 = median progesterone level (nmol/l) 7 days after oocyte retrieval.
hCG, human chorionic gonadotropin; OPU, oocyte pick-up.
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FigUre 1 | Individual mid-luteal serum profiles of progesterone over a 12-h interval in 10 patients undergoing controlled ovarian stimulation for in vitro fertilization 
treatment.
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determined individually based on patient age, BMI, baseline FSH, 
previous response to gonadotropins, and antral follicle count 
and adjusted by monitoring follicular size by transvaginal ultra-
sound during treatment. Final oocyte maturation was induced 
with either hCG 10,000  IU SC (Pregnyl®, MSD, Denmark) or 
6,500 IU SC (Ovitrelle®, Merck Biopharma, Denmark) when two 
or more leading follicles reached a mean diameter of 17  mm. 
Oocyte retrieval was carried out 36 h after hCG administration. 
IVF/ICSI procedures and embryo culture were performed accord-
ing to normal clinical practice. A maximum of two embryos were 
transfered on day 3 or day 5 after oocyte retrieval. Luteal phase 
support was given as vaginal micronized P4 (Lutinus® 300  mg 
daily, Ferring Pharmaceutical, Denmark or Crinone® 180  mg 
daily, Merck Biopharma, Denmark) starting 1  day after oocyte 
pick-up (OPU).
In four patients the GnRH antagonist protocol was used. 
On day 2 of the cycle ovarian stimulation commenced with 
either r-FSH (Gonal-F®; Merck Biopharma, Denmark) or hMG 
(Menopur®, Ferring Pharmaceuticals, Denmark) after a vaginal 
ultrasound examination. Daily GnRH antagonist co-treatment 
(Orgalutran® 0.25  mg/day, MSD, Denmark) was added at a 
follicle size of 12 mm. The FSH dose was individually adjusted 
according to the ovarian response. Final oocyte maturation was 
induced with SC Buserelin 0.5 mg (Suprefact®; Sanofi, Denmark) 
as soon as two or more follicles of ≥17 mm were present. Oocyte 
retrieval was carried out 36 h later. A maximum of two embryos 
were transferred on day 3 or day 5 after OPU. Luteal phase sup-
port was given in an individualized regimen consisting of vaginal 
administration of 300 mg micronized P4 daily (Lutinus®, Ferring 
Pharmaceuticals, Denmark) in combination with a bolus of hCG 
(1,000–1,500  IU) on the day of oocyte retrieval (5, 10). Based 
on the individual ovarian response to stimulation, some patients 
received an additional hCG bolus on OPU + 5 (500–1,000 IU) 
(10). See Table 1 for details. Vaginal P4 administration continued 
until the day of pregnancy testing (hCG trigger) or until seventh 
gestational week (GnRHa trigger).
blood sampling
Blood sampling was conducted during the mid-luteal phase, 
i.e., 7  days after OPU (OPU +  7). Patients were admitted to 
the fertility unit early in the morning and stayed at the clinic 
for the subsequent 12  h. The starting time for blood sampling 
was between 6 a.m. and 9 a.m. for all patients. Participants were 
allowed normal daily life activities during the study period.
An intravenous cannula was inserted into a vein in the ante-
cubital fossa and blood samples (4 ml) were drawn every 60 min 
for 12 h (n = 10) and for two of these hours every 15 min (n = 8 
because of difficult venous access in two patients). After coagula-
tion at room temperature, blood samples were centrifuged and 
serum was isolated and stored at −80°C until analysis.
hormone Measurement
Serum P4 (nmol/l), E2 (pmol/l), and LH (IU/l) concentrations were 
measured using automated electro chemiluminescent immu-
noassays (Cobas® Modular analytics E170, Roche Diagnostics, 
Switzerland) routinely used for analysis at Department of 
Biochemistry, Viborg Regional Hospital, Denmark. All measure-
ments were performed according to manufacturer’s instructions 
using a commercially available chemiluminescent immunoassay 
kit intended for measurements in serum.
The detection limit of hormones was 0.2 nmol/l, 18.4 pmol/l, 
and 0.1 IU/l for P4, E2, and LH, respectively. All serum samples 
from each patient were measured within the same assay run. 
All hormone concentrations above the assay detection limit were 
measured in duplicate. The intra-assay coefficients of variation 
for P4, E2, and LH were all below 4%.
FigUre 2 | (a) Daytime variation in mid-luteal s-progesterone and s-LH in 
patient #2. Median P4 = 283 nmol/l. Maximal variation P4/12 h = 265 nmol/l. 
(b) Daytime variation in mid-luteal s-progesterone and s-estradiol in patient 
#2. Median E2 = 3,471 pmol/l. Maximal variation E2/12 h = 1,481 pmol/l.
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statistics
Data are presented as mean ± SD or median and range when appro-
priate. The maximum absolute variation (MAV) in serum P4 over a 
12-h period is given as the maximum P4 concentration − minimum 
P4 concentration during the time of sampling for each patient.
Spearman’s correlation coefficient (r) was calculated to cor-
relate median steroid levels with the maximum absolute hormone 
variation during the day (MAV). A p value < 0.05 was considered 
to be statistically significant. All analyses were performed using 
STATA, version 13.
ethics
The study was conducted according to the declaration of Helsinki 
for Medical Research and approved by the local Ethics Committee 
of the Central Denmark Region. ClinicalTrial.gov registration 
number NCT02673034.
resUlTs
Patient characteristics
Patients had a mean age of 35.3  ±  4.2  years, mean BMI of 
26.6  ±  4.7  kg/m2 and 1.9  ±  2.0 prior IVF attempts. Median 
level of FSH for all patients was 6.55  UI/l (interquartile range 
5.9;7.2 IU/l). All participants were non-smokers. In four patients 
the cause of infertility was non-female (male factor or no male 
partner), in three patients the cause was female (tubal factor or 
endometriosis) and in three patients the cause of infertility was 
idiopathic (unexplained). See Table 1 for details.
Overall Mid-luteal Progesterone Values
Three patients had median mid-luteal P4 levels below 60 nmol/l. 
Two of these patients (#7 and #8) were triggered with a GnRH 
agonist and received luteal phase support with 1,500  IU hCG 
(OPU) and vaginal P4 (Crinone 180  mg daily). Despite having 
19 and 17 follicles ≥ 14 mm and 11–13 mature oocytes retrieved 
at the day of OPU they presented with a mid-luteal P4 of only 
55 and 36  nmol/l, respectively. The other patient (#9) with 
P4 < 60 nmol/l was triggered with 10,000 IU hCG and had seven 
follicles > 14 mm at the day of aspiration.
Overall Mid-luteal lh Values
None of the patients downregulated in a long GnRH agonist pro-
tocol (n = 6) had s-LH levels above the detection limit of the assay 
at any point during measurement (i.e., LH < 0.1 IU/l). In three 
of the four patients stimulated in the GnRH antagonist protocol 
a modest LH pulse activity was seen with LH amplitudes ranging 
from 0.2 to 2.8 UI/l. In all patients, the LH peak was followed by 
an increase in serum P4 ranging from 4 to 36 nmol/l.
Daytime Variation in serum Progesterone
As seen during the natural cycle, large fluctuations in mid-luteal P4 
were also present during daytime in some of the women under-
going IVF treatment (Figure 1). Fluctuations in luteal steroids 
were seen independent of the choice of stimulation protocol, the 
mode of final oocyte maturation and the type of luteal phase 
support.
The largest variation in P4 levels was seen in patients with 
median P4  >  250  nmol/l. In patient #2 with a median P4 of 
283 nmol/l, P4 fluctuated from 293 nmol/l at 11 a.m. to 448 nmol/l 
at 12 p.m.—i.e., an increase of 155 nmol/l within 1 h. This fluctua-
tion in P4 level was present even though s-LH was under the detec-
tion level throughout the day (Figure 2A). The increase in P4 was 
accompanied by a comparable increase in E2 (Figure 2A). Serum 
P4 concentrations during the 12-h period for that specific patient 
ranged from 183 nmol/l early in the morning to 448 nmol/l during 
the day—thus, a MAV during the study period of Δ265 nmol/l. 
In patient #6 (median P4 376  nmol/l) and #3 (median P4 
277  nmol/l) a rapid elevation of P4 levels (Δ 70–75  nmol/l, 
respectively) was seen within a period of only 15 min without any 
concomitant LH activity (LH < 0.1 IU/l). In comparison, patient 
#7 had a median P4 of only 36 nmol/l and showed only minor 
fluctuations throughout the day with P4 levels ranging from 25 to 
48 nmol/l following a small detectable increase in LH secretion 
(see Table 2 for complete daytime P4 values).
There was a positive correlation between median P4 levels and 
MAV in P4 during daytime (Spearman’s r = 0.9273, p = 0.0001). 
Table 2 | Mid-luteal serum progesterone concentrations during daytime in 10 women undergoing in vitro fertilization treatment.
Patient Median P4 
(range)
1
Time 8.00 a.m. 9.00 a.m. 9.15 a.m. 9.30 a.m. 9.45 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m.
P4 nmol/l 126 106 91 93 88 97 87 93 99 107
15 p.m. 16 p.m. 17 p.m. 17.15 p.m. 17.30 p.m. 17.45 p.m. 18 p.m. 19 p.m. 20 p.m. 89 (63–126)
102 89 69 72 78 78 73 67 63 ΔP4: 63
2
Time 8.00 a.m. 9.00 a.m. 10.00 a.m. 10.15 a.m. 10.30 a.m. 10.45 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m.
P4 nmol/l 183 224 283 271 266 283 293 448 249 249
15.00 p.m. 15.15 p.m. 15.30 p.m. 15.45 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 19.00 p.m. 20.00 p.m. 283 (183–448)
262 258 345 328 342 331 348 387 294 ΔP4: 265
3
Time 6.00 a.m. 7.00 a.m. 7.15 a.m. 7.30 a.m. 7.45 a.m. 8.00 a.m. 9.00 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m.
P4 nmol/l 370 320 323 301 272 347 281 244 235 301
12.15 p.m. 12.30 p.m. 12.45 p.m. 13.00 p.m. 14.00 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 277 (225–370)
283 269 277 278 230 225 251 255 232 ΔP4: 145
4
Time 8.00 a.m. 8.15 a.m. 8.30 a.m. 8.45 a.m. 9.00 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m.
P4 nmol/l 216 228 224 228 216 226 202 240 213 222
14.15 p.m. 14.30 p.m. 14.45 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 19.00 p.m. 20.00 p.m. 213 (171–240)
208 205 200 201 228 204 188 190 171 ΔP4: 69
5
Time 9.00 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m.
P4 nmol/l 131 122 110 119 136 97 92 89 70 77
19.00 p.m. 20.00 p.m. 21.00 p.m. 97 (70–136)
70 96 71 ΔP4: 66
6
Time 7.00 a.m. 8.00 a.m. 9.00 a.m. 10.00 a.m. 11.00 a.m. 11.15 a.m. 11.30 a.m. 11.45 a.m. 12.00 p.m. 13.00 p.m.
P4 nmol/l 416 296 311 299 365 314 312 382 413 414
13.15 p.m. 13.30 p.m. 13.45 p.m. 14.00 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 19.00 p.m. 376 (275–440)
416 395 307 275 366 438 395 440 376 ΔP4: 165
7
Time 7.00 a.m. 8.00 a.m. 9.00 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m. 15.00 p.m. 16.00 p.m.
P4 nmol/l 27 25 32 36 40 39 36 34 29 29
17.00 p.m. 18.00 p.m. 19.00 p.m. 36 (25–48)
39 48 37 ΔP4: 23
8
Time 7.00 a.m. 8.00 a.m. 9.00 a.m. 9.15 a.m. 9.30 a.m. 9.45 a.m. 10.00 a.m. 11.00 a.m. 12.00 p.m. 13.00 p.m.
P4 nmol/l 51 55 50 50 50 49 50 53 59 59
14.00 p.m. 15.00 p.m. 16.00 p.m. 16.15 p.m. 16.30 p.m. 16.45 p.m. 17.00 p.m. 18.00 p.m. 19.00 p.m. 55 (49–62)
52 53 61 59 60 59 62 58 56 ΔP4: 13
9
Time 7.00 a.m. 8.00 a.m. 9.00 a.m. 10.00 a.m. 11.00 a.m. 11.15 a.m. 11.30 a.m. 11.45 a.m. 12.00 p.m. 13.00 p.m.
P4 nmol/l 65 64 63 58 52 52 50 51 51 59
14.00 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 18.15 p.m. 18.30 p.m. 18.45 p.m. 19.00 p.m. 54 (51–65)
54 58 55 58 56 53 53 53 52 ΔP4: 14
10
Time 7.00 a.m. 8.00 a.m. 8.15 a.m. 8.30 a.m. 8.45 a.m. 9.00 a.m. 10.00 a.m. 10.15 a.m. 10.30 a.m. 10.45 a.m.
P4 nmol/l 185 178 187 182 181 180 112 108 117 124
11.00 a.m. 12.00 p.m. 13.00 p.m. 14.00 p.m. 15.00 p.m. 16.00 p.m. 17.00 p.m. 18.00 p.m. 19.00 p.m. 161 (108–189)
122 140 155 153 172 189 18 161 146 ΔP4: 81
ΔP4 = individual maximum absolute variation in P4 during daytime = maximum P4 − minimum P4 concentration (nmol/l).
P4 SI conversion factor: nmol/l = 3.18*ng/ml.
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The magnitude of P4 pulses and thus the maximum variation is 
dependent on the median mid-luteal P4 concentration (Figure 3). 
In patients with median P4 > 250 nmol/l, very large fluctuations 
in serum P4 were seen during daytime with a median MAV 
of 165  nmol/l (range 145–265  nmol/l). Patients with median 
P4 between 89 and 213 nmol/l had median MAV of 68 nmol/l 
(range 63–81 nmol/l), whereas patients with very low mid-luteal 
P4 levels (median P4 <  60  nmol/l) had fairly constant serum 
FigUre 4 | Time for maximum P4 concentration (acrophase) in 10 women 
undergoing IVF treatment. As seen, five women had their P4 acrophase 
before noon and five after noon. The same pattern was seen for P4 nadir.
FigUre 3 | Maximum absolute variation in s-progesterone = P4 
maximum − P4 minimum (nmol/l) in 10 patients undergoing in vitro fertilization 
treatment. Spearman’s r = 0.9273, p = 0.0001.
7
Thomsen et al. Daytime Variation in Luteals-Progesterone
Frontiers in Endocrinology | www.frontiersin.org March 2018 | Volume 9 | Article 92
individual maximum E2 variations (Max E2 − Min E2) over 12 h 
ranging from Δ404 to Δ1,481 pmol/l. There was no correlation 
between median E2 levels and MAV in mid-luteal E2 (Spearman’s 
r = 0.4424, p = 0.20).
As expected, P4 and E2 seem to be co-secreted from the CL 
showing similar patterns of fluctuations over time (Figure  5). 
Patients with median P4 < 60 nmol/l had E2 ranging from 541 
to 1,552 pmol/l (median E2 1,457 pmol/l) whereas patients with 
median P4 between 89 and 213 nmol/l had E2 levels from 659 to 
4,884 pmol/l (median E2 2,843 pmol/l). In patients with median 
P4 > 250 nmol/l, E2 ranged from 3,471 to 3,919 pmol/l (median 
E2 3,874  pmol/l). There was a significant correlation between 
median P4 levels and median E2 levels during mid-luteal phase of 
the stimulated cycle (Spearman’s r = 0.8424, p = 0.002).
DiscUssiOn
To the best of our knowledge, this is the first study to explore a 
possible daytime variation in P4 secretion during the mid-luteal 
phase in a group of women undergoing IVF treatment.
We found that the magnitude of mid-luteal P4 fluctuations fol-
lowing IVF treatment was dependent on the median P4 level. The 
largest P4 variations were seen in patients with median P4 exceed-
ing 250 nmol/l (median MAV 165 nmol/l), whereas patients in 
the low P4 group (median P4 < 60 nmol/l) had relatively constant 
P4 levels throughout the day (median MAV 14 nmol/l). Patients 
showed a highly individual hormone secretion pattern without 
any obvious common daytime rhythm in P4 secretion. Serum 
E2 showed similar fluctuations in the mid-luteal phase with 
patients having individual E2 variations ranging from Δ404 to 
Δ1,481 pmol/l during the 12-h study time.
Earlier studies described the highly variable pattern of P4 
secretion during the mid-luteal phase of naturally cycling 
women (15, 19, 20). These studies reported the presence of 
two distinguishable types of luteal P4 pulses—some preceded 
by a LH pulse and others non-concomitant to LH seen during 
time of pituitary quiescence. The latter seems to be the result 
of an autonomous P4 secretion from the CL, triggered and 
maintained by intraovarian concentrations of E2, oxytocin, and 
PGF2α (21, 22). The CL consists of two types of steroidogenic 
cells, i.e., the small luteal cells (SLCs) derived from follicular 
theca cells and the large luteal cells (LLCs) originating from 
follicular granulosa cells. Both the small and the large cells 
have extensive capacity to produce P4. Moreover, both cells 
have unique steroidogenic functions and the “two-cell” 
mechanism of E2 biosynthesis appear to operate in the human 
CL analogous to the preovulatory follicle (23). Thus, the LLCs 
contain P450-aromatase essential for E2 synthesis whereas SLCs 
express P450c17 for androgen production (24, 25). Both types 
of luteal cells express E2 receptors (26) and E2 stimulation is a 
powerful trigger of P4 release from either cell type (27).
Isolation of large and SLCs from human corpora lutea has 
shown that once induced by the LH peak, the LLCs exhibit the 
greatest basal P4 production (28) and that this production is not 
increased by further LH stimulation (29). The LLCs produce P4 
at a constant rate and are the dominant source of P4 during the 
P4 levels throughout the day (median MAV 14  nmol/l, range 
13–23 nmol/l).
There was no common general daytime rhythm for P4 in the 
10 women examined, suggesting that the luteal phase is patient 
specific. Some patients had their highest hormone levels in the 
morning—others peaked during the day or in the early evening 
(see Figure 1). The time of P4 acrophase (zenith) and P4 nadir was 
before noon in half of the patients and after noon in the other half 
of patients (Figure 4).
Daytime Variation in serum estradiol
Large fluctuations in mid-luteal serum E2 were also seen during 
the 12-h sampling time. In patient #2, E2 increased from 3,480 to 
4,664 pmol/l in 1 h (Δ1,184 nmol/l) (Figure 2B). Patients had 
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early luteal phase (30). During this period, the P4 levels exhibit 
a non-pulsatile pattern both in the natural (15) and stimulated 
cycle (OPU + 2) (31). The responsivity of the SLCs to LH/hCG 
develops during the early mid-luteal phase where cells respond 
with a pronounced increase in P4 secretion in response to LH 
pulses. The luteal P4 contribution from the SLCs increase during 
the mid-and late luteal phase during which P4 secretion becomes 
highly pulsatile (32).
Thus, the endogenous mid-luteal P4 level consist of three 
parts—the basal P4 production from the LLCs, the P4 pulses from 
SLCs triggered by pituitary LH, and the autonomous P4 fluctua-
tions independent of luteotrophic stimuli.
Previously, Wuttke et  al. proposed a model to explain the 
LH-independent fluctuations in mid-luteal P4 levels based on 
autocrine and paracrine mechanisms in the luteal tissue (21). 
Upon stimulation with LH during the mid-luteal phase, the SLCs 
start secretion of P4 as well as androstenedione—the latter is subse-
quently converted to E2 in LLCs by P450-aromatase. The increased 
E2 concentration acts in an autocrine way in LLCs to increase the 
release of both P4 and oxytocin. Oxytocin stimulates fibroblasts 
to release PGF2α, which in turn stimulates further oxytocin as 
well as E2 secretion from the luteal cells. The isolated effect of 
oxytocin and PGF2α upon the luteal cell lines is a decreased P4 
secretion, but this effect is overridden by the concomitantly trig-
gered increase in E2 which will elicit a pronounced P4 release. In 
this way, the LH pulse will stimulate an intra-luteal circuit involv-
ing auto-and paracrine effects of E2, oxytocin, PGF2α—and pos-
sible a variety of other regulatory peptides, i.e., Substance P—and 
the net effect is the generation of a P4 pulse. This circuit functions 
for hours without further gonadotropic support, thus generating 
several P4 pulses with gradually decreasing amplitude until the 
next LH pulse sets off the intra-luteal E2/P4 loop again. In con-
trast, in women with hypothalamic deficiency with suppressed 
LH levels and no LH pulses, mid-luteal P4 shows a non-pulsatile 
pattern, underlining the need for an initial high LH/hCG load 
to trigger the P4 circuit (21). The oxytocin induced P4 release 
can be prevented by treatment of the CL with tamoxifen—an 
estrogen receptor blocking agent—underlining the E2 regulation 
of the autonomous P4 pulses (27). This independent intra-luteal 
P4 pulse generator might serve as an additional biological safety 
mechanism preventing declining P4 levels in between LH pulses 
and might explain the function of the substantial E2 production 
during the luteal phase in humans.
In the stimulated IVF cycle, LH pulses are absent during the 
mid-luteal phase and serum LH levels are distinctly suppressed 
(33). The hCG bolus administered for ovulation induction or 
as luteal phase support exerts a tonic and constant stimulation 
on the luteal tissue due to the prolonged half-life of hCG and, 
therefore, cannot account for the rapid P4 fluctuations seen 
during the mid-luteal phase in this study. The standard vaginal 
P4 supplementation reaches steady state during the early luteal 
phase and contributes with remarkably constant serum P4 levels 
though out the day despite multiple daily vaginal doses (34). The 
very large fluctuations in serum P4 seen in the present study are, 
therefore, likely to be the result of the autonomous intraovarian 
P4 circuit. This is further emphasized by the fact that P4 peaks are 
accompanied by concomitant E2 rises and exogenous E2 was not 
provided as part of the luteal phase support.
We were not able to detect a common general pattern of P4 
secretion during daytime in the 10 patients examined. The peak 
and nadir P4 levels occurred at different times in different patients, 
and the course of hormone levels during the day showed highly 
individual rhythms. This is in agreement with studies performed 
during the mid-luteal phase of the natural cycle (3, 19). In a 
study of seven women studied over 24 h in the mid-luteal phase 
of the natural cycle, the P4 acrophase varied from 10.31  a.m. 
to 11.33 p.m. (16). Based on the lack of a diurnal reproducible 
pattern for mid-luteal P4 in the IVF cycle the accuracy of the P4 
measurement is not improved by a fixed timing of blood sampling 
and, thus, the P4 measurement could be performed at any time 
during clinic opening hours.
During the natural cycle both late follicular E2 levels, follicular 
diameter at the time of ovulation as well as area under the LH 
surge curve correlate poorly to the subsequent luteal phase P4 level 
(3). Thus, predicting patients with insufficient luteal P4 levels is 
troublesome based on the follicular development as abnormal 
luteal phases can be seen in cycles characterized by normal follicu-
logenesis (35). In the present study, the two patients with the lowest 
P4 levels (36 and 55 nmol/l) had 17 and 19 follicles, respectively, on 
the day of OPU, showing that a large number of CLs do not warrant 
FigUre 5 | (a) Daytime variation in mid-luteal s-progesterone and 
s-estradiol in patient #10. Median P4 = 161 nmol/l, median 
E2 = 3,606 pmol/l. (b) Daytime variation in mid-luteal s-progesterone and 
s-estradiol in patient #1. Median P4 = 89 nmol/l, median E2 = 659 pmol/l.
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a high P4 output in the luteal phase. For this reason monitoring 
of luteal phase P4 could be of value to detect patients with low P4 
levels, who might benefit from additional exogenous P4 therapy. 
However, the prerequisite for easy luteal phase monitoring is that 
the validity of a single measured P4 value is reliable and gives a 
reasonable estimate of the CL capacity of the patient.
We acknowledge that the small sample size of this study 
may limit the validity of general interpretations. However, we 
consider this explorative preliminary study to be pioneering as 
part of basic research and, importantly, it is the first to explore 
the mid-luteal P4 fluctuations in different types of IVF cycles. The 
autonomous LH-independent P4 bursts from the ovaries during 
the mid-luteal phase were seen in both GnRH analog types 
(GnRH antagonist and long GnRHa protocol) as well as after 
different types of triggering of final oocyte maturation (hCG or 
GnRH agonist). Thus, it seems that these autonomous episodic 
luteal P4 peaks are generated independently of the choice of 
treatment regimen and may, therefore, also apply to other IVF 
stimulation protocols.
cOnclUsiOn
Based on the 10 women examined in this study, we state that the 
accuracy of a single mid-luteal serum progesterone measure-
ment as an approximation of mean P4 levels throughout the day 
depends on the P4 concentration and that women with low P4 
levels (P4 < 60 nmol/l) exhibit clinically stable P4 levels during 
daytime. Thus, a single P4 measurement in the low progesterone 
patient reflects quite accurately the CL function and a measured 
low P4 value can, therefore, be regarded as a “true low value.” 
Future studies should clarify, whether additional exogenous 
P4 support administered to the low luteal P4 patient group can 
improve the reproductive outcome.
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